Pirfenidone is renoprotective in diabetic kidney disease

Journal of the American Society of Nephrology

Volumn 20, Issue 8, 2009, Pages 1765-1775

  RamachandraRao, Satish P ^a,d,e   Zhu, Yanqing ^e   Ravasi, Timothy ^b,c   McGowan, Tracy A ^e   Toh, Irene ^e   Dunn, Stephen R ^e,f   Okada, Shinichi ^a,d   Shaw, Michael A ^e   Sharma, Kumar ^a,d,e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Scripps NeuroAIDS Preclinical Studies Centre   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; REACTIVE OXYGEN METABOLITE; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ELECTROSPRAY MASS SPECTROMETRY; KIDNEY FIBROSIS; LIQUID CHROMATOGRAPHY; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; RENAL PROTECTION; RNA PROCESSING;

EID: 68149178848     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2008090931     Document Type: Article

References (67)

1. State-specific trends in chronic kidney failure-United States, 1990- 2001. MMWR Morb Mortal Wkly Rep 53: 918-920, 2004
2. Ewens KG, George RA, Sharma K, Ziyadeh FN, Spielman RS: Assessment of 115 candidate genes for diabetic nephropathy by transmission/ disequilibrium test. Diabetes 54: 3305-3318, 2005 (Pubitemid 43336530)
3. Fioretto P, Steffes MW, Brown DM, Mauer SM: An overview of renal pathology in insulin-dependent diabetes mellitus in relationship to altered glomerular hemodynamics. Am J Kidney Dis 20: 549-558, 1992 (Pubitemid 23031703)
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensinconverting- enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993
5. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001 (Pubitemid 34940825)
6. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001 (Pubitemid 34940824)
7. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 342: 381-389, 2000
8. Danesh FR, Kanwar YS: Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J 18: 805-815, 2004 (Pubitemid 38544499)
9. Ziyadeh FN, Sharma K: Overview: Combating diabetic nephropathy. J Am Soc Nephrol 14: 1355-1357, 2003
10. Hasslacher C, Ritz E, Wahl P, Michael C: Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 4: 859-863, 1989 (Pubitemid 20031053)
11. USRDS: The United States Renal Data System. Am J Kidney Dis 42[Suppl 5]: 1-230, 2003
12. ASHP therapeutic position statement on strict glycemic control in patients with diabetes. Am J Health Syst Pharm 60: 2357-2362, 2003
13. Benjamin SM, Valdez R, Geiss LS, Rolka DB, Narayan KM: Estimated number of adults with prediabetes in the US in 2000: Opportunities for prevention. Diabetes Care 26: 645-649, 2003
14. Breyer MD: Diabetic nephropathy: Introduction. Semin Nephrol 27: 129, 2007
15. Greenwald A: Current nutritional treatments of obesity. Adv Psychosom Med 27: 24-41, 2006
16. Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BR, Kurnik PB, Weisberg LS: Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 46: 854-859, 1997 (Pubitemid 27188264)
17. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 90: 1814-1818, 1993
18. Taniyama M, Ohbayashi S, Narita M, Nakazawa R, Hasegawa S, Azuma N, Teraoka S, Ota K, Yamauchi S, Margolin SB: Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients. Eur J Clin Pharmacol 52: 77-78, 1997 (Pubitemid 27168216)
19. Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB: Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2: 906-913, 2007
20. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, Kudoh S: Double-blind, placebocontrolled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171: 1040-1047, 2005 (Pubitemid 40616955)
21. Hoffman BB, Sharma K, Zhu Y, Ziyadeh FN: Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration. Kidney Int 54: 1107-1116, 1998 (Pubitemid 28449897)
22. Hu T, Ramachandrarao SP, Siva S, Valancius C, Zhu Y, Mahadev K, Toh I, Goldstein BJ, Woolkalis M, Sharma K: Reactive oxygen species production via NADPH oxidase mediates TGF-beta-induced cytoskeletal alterations in endothelial cells. Am J Physiol Renal Physiol 289: F816-F825, 2005 (Pubitemid 41324203)
23. Misra HP, Rabideau C: Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem 204: 119-126, 2000
24. Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, Berriz GF, Gibbons FD, Dreze M, Ayivi-Guedehoussou N, Klitgord N, Simon C, Boxem M, Milstein S, Rosenberg J, Goldberg DS, Zhang LV, Wong SL, Franklin G, Li S, Albala JS, Lim J, Fraughton C, Llamosas E, Cevik S, Bex C, Lamesch P, Sikorski RS, Vandenhaute J, Zoghbi HY, Smolyar A, Bosak S, Sequerra R, Doucette-Stamm L, Cusick ME, Hill DE, Roth FP, Vidal M: Towards a proteome-scale map of the human protein-protein interaction network. Nature 437: 1173-1178, 2005 (Pubitemid 41509356)
25. Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, Goehler H, Stroedicke M, Zenkner M, Schoenherr A, Koeppen S, Timm J, Mintzlaff S, Abraham C, Bock N, Kietzmann S, Goedde A, Toksoz E, Droege A, Krobitsch S, Korn B, Birchmeier W, Lehrach H, Wanker EE: A human protein-protein interaction network: A resource for annotating the proteome. Cell 122: 957-968, 2005 (Pubitemid 41345212)
26. Ramani AK, Bunescu RC, Mooney RJ, Marcotte EM: Consolidating the set of known human protein-protein interactions in preparation for large-scale mapping of the human interactome. Genome Biol 6: R40, 2005
27. Alfarano C, Andrade CE, Anthony K, Bahroos N, Bajec M, Bantoft K, Betel D, Bobechko B, Boutilier K, Burgess E, Buzadzija K, Cavero R, D'Abreo C, Donaldson I, Dorairajoo D, Dumontier MJ, Dumontier MR, Earles V, Farrall R, Feldman H, Garderman E, Gong Y, Gonzaga R, Grytsan V, Gryz E, Gu V, Haldorsen E, Halupa A, Haw R, Hrvojic A, Hurrell L, Isserlin R, Jack F, Juma F, Khan A, Kon T, Konopinsky S, Le V, Lee E, Ling S, Magidin M, Moniakis J, Montojo J, Moore S, Muskat B, Ng I, Paraiso JP, Parker B, Pintilie G, Pirone R, Salama JJ, Sgro S, Shan T, Shu Y, Siew J, Skinner D, Snyder K, Stasiuk R, Strumpf D, Tuekam B, Tao S, Wang Z, White M, Willis R, Wolting C, Wong S, Wrong A, Xin C, Yao R, Yates B, Zhang S, Zheng K, Pawson T, Ouellette BF, Hogue CW: The Biomolecular Interaction Network Database and related tools 2005 update. Nucleic Acids Res 33: D418- D424, 2005 (Pubitemid 40207907)
28. Joshi-Tope G, Gillespie M, Vastrik I, D'Eustachio P, Schmidt E, de Bono B, Jassal B, Gopinath GR, Wu GR, Matthews L, Lewis S, Birney E, Stein L: Reactome: A knowledgebase of biological pathways. Nucleic Acids Res 33: D428-D432, 2005
29. Peri S, Navarro JD, Amanchy R, Kristiansen TZ, Jonnalagadda CK, Surendranath V, Niranjan V, Muthusamy B, Gandhi TK, Gronborg M, Ibarrola N, Deshpande N, Shanker K, Shivashankar HN, Rashmi BP, Ramya MA, Zhao Z, Chandrika KN, Padma N, Harsha HC, Yatish AJ, Kavitha MP, Menezes M, Choudhury DR, Suresh S, Ghosh N, Saravana R, Chandran S, Krishna S, Joy M, Anand SK, Madavan V, Joseph A, Wong GW, Schiemann WP, Constantinescu SN, Huang L, Khosravi-Far R, Steen H, Tewari M, Ghaffari S, Blobe GC, Dang CV, Garcia JG, Pevsner J, Jensen ON, Roepstorff P, Deshpande KS, Chinnaiyan AM, Hamosh A, Chakravarti A, Pandey A: Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res 13: 2363-2371, 2003 (Pubitemid 37266003)
30. Vastrik I, D'Eustachio P, Schmidt E, Joshi-Tope G, Gopinath G, Croft D, de Bono B, Gillespie M, Jassal B, Lewis S, Matthews L, Wu G, Birney E, Stein L: Reactome: A knowledge base of biologic pathways and processes. Genome Biol 8: R39, 2007 (Pubitemid 351851050)
31. Flynn A, Proud CG: The role of eIF4 in cell proliferation. Cancer Surv 27: 293-310, 1996
32. Kasinath BS, Mariappan MM, Sataranatarajan K, Lee MJ, Feliers D: mRNA translation: unexplored territory in renal science. J Am Soc Nephrol 17: 3281-3292, 2006 (Pubitemid 44865271)
33. Mariappan MM, Feliers D, Mummidi S, Choudhury GG, Kasinath BS: High glucose, high insulin, and their combination rapidly induce laminin- beta1 synthesis by regulation of mRNA translation in renal epithelial cells. Diabetes 56: 476-485, 2007 (Pubitemid 46263079)
34. Waskiewicz AJ, Johnson JC, Penn B, Mahalingam M, Kimball SR, Cooper JA: Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol 19: 1871-1880, 1999
35. Kleijn M, Scheper GC, Voorma HO, Thomas AA: Regulation of translation initiation factors by signal transduction. Eur J Biochem 253: 531-544, 1998 (Pubitemid 28223517)
36. Giri SN, Leonard S, Shi X, Margolin SB, Vallyathan V: Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol 18: 169-177, 1999
37. Gunther A, Markart P, Eickelberg O, Seeger W: Pulmonary fibrosis: A therapeutic dilemma? [in German]. Med Klin (Munich) 101: 308-312, 2006
38. Chen S, Iglesias-de la Cruz MC, Jim B, Hong SW, Isono M, Ziyadeh FN: Reversibility of established diabetic glomerulopathy by anti-TGFbeta antibodies in db/db mice. Biochem Biophys Res Commun 300: 16-22, 2003 (Pubitemid 36042924)
39. Okamoto A, Kawamura T, Kanbe K, Kanamaru Y, Ogawa H, Okumura K, Nakao A: Suppression of serum IgE response and systemic anaphylaxis in a food allergy model by orally administered high-dose TGFbeta. Int Immunol 17: 705-712, 2005 (Pubitemid 41417968)
40. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 97: 8015-8020, 2000 (Pubitemid 30460765)
41. Hewitson TD, Kelynack KJ, Tait MG, Martic M, Jones CL, Margolin SB, Becker GJ: Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 14: 453-460, 2001 (Pubitemid 34168279)
42. Park HS, Bao L, Kim YJ, Cho IH, Lee CH, Hyun BH, Margolin SB, Park YH: Pirfenidone suppressed the development of glomerulosclerosis in the FGS/Kist mouse. J Korean Med Sci 18: 527-533, 2003 (Pubitemid 38030519)
43. Shimizu T, Fukagawa M, Kuroda T, Hata S, Iwasaki Y, Nemoto M, Shirai K, Yamauchi S, Margolin SB, Shimizu F, Kurokawa K: Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl 63: S239-S243, 1997 (Pubitemid 28020482)
44. Harris DC, Rangan GK: Retardation of kidney failure: Applying principles to practice. Ann Acad Med Singapore 34: 16-23, 2005
45. Mirkovic S, Seymour AM, Fenning A, Strachan A, Margolin SB, Taylor SM, Brown L: Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol 135: 961-968, 2002 (Pubitemid 34214455)
46. Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izumi T: Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 41: 1118-1123, 2002 (Pubitemid 36150010)
47. Buleon M, Allard J, Jaafar A, Praddaude F, Dickson Z, Ranera MT, Pecher C, Girolami JP, Tack I: Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model. Am J Physiol Renal Physiol 294: F1249-F1256, 2008
48. Cheng Q, Law PK, de Gasparo M, Leung PS: Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl) ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2′-(1H-tetrazol-5-yl)- [1,1′-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes. J Pharmacol Exp Ther 327: 683-691, 2008
49. Chu KY, Lau T, Carlsson PO, Leung PS: Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 55: 367-374, 2006 (Pubitemid 43343265)
50. Chu KY, Leung PS: Angiotensin II type 1 receptor antagonism mediates uncoupling protein 2-driven oxidative stress and ameliorates pancreatic islet beta-cell function in young type 2 diabetic mice. Antioxid Redox Signal 9: 869-878, 2007
51. Guo Z, Su W, Allen S, Pang H, Daugherty A, Smart E, Gong MC: COX-2 up-regulation and vascular smooth muscle contractile hyperreactivity in spontaneous diabetic db/db mice. Cardiovasc Res 67: 723-735, 2005 (Pubitemid 41033368)
52. Kosugi R, Shioi T, Watanabe-Maeda K, Yoshida Y, Takahashi K, Machida Y, Izumi T: Angiotensin II receptor antagonist attenuates expression of aging markers in diabetic mouse heart. Circ J 70: 482-488, 2006
53. Nakayama M, Inoguchi T, Sonta T, Maeda Y, Sasaki S, Sawada F, Tsubouchi H, Sonoda N, Kobayashi K, Sumimoto H, Nawata H: Increased expression of NAD(P)H oxidase in islets of animal models of type 2 diabetes and its improvement by an AT1 receptor antagonist. Biochem Biophys Res Commun 332: 927-933, 2005 (Pubitemid 40798176)
54. Black DL: Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 72: 291-336, 2003 (Pubitemid 36930448)
55. Mauger DM, Lin C, Garcia-Blanco MA: hnRNP H and hnRNP F complex with Fox proteins to silence FGFR2 exon IIIc. Mol Cell Biol 28: 5403-5419, 2008
56. Chaudhary N, McMahon C, Blobel G: Primary structure of a human arginine-rich nuclear protein that colocalizes with spliceosome components. Proc Natl Acad Sci U S A 88: 8189-8193, 1991 (Pubitemid 21915322)
57. Haynes C, Iakoucheva LM: Serine/arginine-rich splicing factors belong to a class of intrinsically disordered proteins. Nucleic Acids Res 34: 305-312, 2006 (Pubitemid 43160053)
58. Lopato S, Waigmann E, Barta A: Characterization of a novel arginine/ serine-rich splicing factor in Arabidopsis. Plant Cell 8: 2255-2264, 1996 (Pubitemid 126446962)
59. Feliers D, Lee MJ, Ghosh-Choudhury G, Bomsztyk K, Kasinath BS: Heterogeneous nuclear ribonucleoprotein K contributes to angiotensin II stimulation of vascular endothelial growth factor mRNA translation. Am J Physiol Renal Physiol 293: F607-F615, 2007 (Pubitemid 47358133)
60. Sataranatarajan K, Mariappan MM, Lee MJ, Feliers D, Choudhury GG, Barnes JL, Kasinath BS: Regulation of elongation phase of mRNA translation in diabetic nephropathy: Amelioration by rapamycin. Am J Pathol 171: 1733-1742, 2007
61. Wolf G, Haberstroh U, Neilson EG: Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 140: 95-107, 1992
62. Tsuchida, K-I, Zhu Y, Siva S, Dunn SR, Sharma K: Role of Smad4 on TGF-b-induced extracellular matrix stimulation in mesangial cells. Kidney Int 63: 2000-2009, 2003
63. Ramachandra Rao SP, Wassell R, Shaw MA, Sharma K: Profiling of human mesangial cell subproteomes reveals a role for calmodulin in glucose uptake. Am J Physiol Renal Physiol 292: F1182-F1189, 2007
64. Islam M, Burke JF Jr, McGowan TA, Zhu Y, Dunn SR, McCue P, Kanalas J, Sharma K: Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. Kidney Int 59: 498-506, 2001 (Pubitemid 32157915)
65. Kim HS, Lee G, John SW, Maeda N, Smithies O: Molecular phenotyping for analyzing subtle genetic effects in mice: application to an angiotensinogen gene titration. Proc Natl Acad Sci U S A 99: 4602-4607, 2002 (Pubitemid 34286031)
66. Williams KJ, Qiu G, Usui HK, Dunn SR, McCue P, Bottinger E, Iozzo RV, Sharma K: Decorin deficiency enhances progressive nephropathy in diabetic mice. Am J Pathol 171: 1441-1450, 2007 (Pubitemid 350158306)
67. Seyer-Hansen K, Hansen J, Gundersen HJ: Renal hypertrophy in experimental diabetes: A morphometric study. Diabetologia 18: 501-505, 1980 (Pubitemid 10114475)